Fátima Martínez-Lozano Aranaga

Dr. Fátima Martínez-Lozano Aranaga


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
AMAlfonso Mesejo
Alfonso Mesejo
JMJuan Carlos Montejo
Juan Carlos Montejo
CVClara Vaquerizo-Alonso
Clara Vaquerizo-Alonso
GLGabriela Lobo-Tamer
Gabriela Lobo-Tamer
MZMercedes Zabarte-Martinez
Mercedes Zabarte-Martinez
FAFátima Martínez-Lozano Aranaga
Fátima Martínez-Lozano Aranaga
Introduction: Although standard enteral nutrition is universally accepted, the use of disease-specific formulas for hyperglycemic patients is still controversial. This study examines whether a high-protein diabetes-specific formula reduces insulin needs, improves glycemic control and reduces ICU-acquired infection in critically ill, hyperglycemic patients on mechanical ventilation (MV). Methods: This was a prospective, open-label, randomized (web-based, blinded) study conducted at nine Spanish ICUs. The patient groups established according to the high-protein formula received were: group A, new-generation diabetes-specific formula; group B, standard control formula; group C, control diabetes-specific formula. Inclusion criteria were: expected enteral nutrition ≥5 days, MV, baseline glucose >126 mg/dL on admission or >200 mg/dL in the first 48 h. Exclusion criteria were: APACHE II ≤10, insulin-dependent diabetes, renal or hepatic failure, treatment with corticosteroids, immunosuppressants or lipid-lowering drugs and body mass index ≥40 kg/m2. The targeted glucose level was 110–150 mg/dL. Glycemic variability was calculated as the standard deviation, glycemic lability index and coefficient of variation. Acquired infections were recorded using published consensus criteria for critically ill patients. Data analysis was on an intention-to-treat basis. Results: Over a 2-year period, 157 patients were consecutively enrolled (A 52, B 53 and C 52). Compared with the standard control formula, the new formula gave rise to lower insulin requirement (19.1 ± 13.1 vs. 23.7 ± 40.1 IU/day, p <0.05), plasma glucose (138.6 ± 39.1 vs. 146.1 ± 49.9 mg/dL, p <0.01) and capillary blood glucose (146.1 ± 45.8 vs. 155.3 ± 63.6 mg/dL, p <0.001). Compared with the control diabetes-specific formula, only capillary glucose levels were significantly reduced (146.1 ± 45.8 vs. 150.1 ± 41.9, p <0.01). Both specific formulas reduced capillary glucose on ICU day 1 (p <0.01), glucose variability in the first week (p <0.05), and incidences of ventilator-associated tracheobronchitis (p <0.01) or pneumonia (p <0.05) compared with the standard formula. No effects of the nutrition formula were produced on hospital stay or mortality. Conclusions: In these high-risk ICU patients, both diabetes-specific formulas lowered insulin requirements, improved glycemic control and reduced the risk of acquired infections relative to the standard formula. Compared with the control-specific formula, the new-generation formula also improved capillary glycemia. Trial registration: Clinicaltrials.gov NCT1233726.

Verified
Journal Article
Open access
PDF file
NCNerea Cuartero
Nerea Cuartero
FAFátima Martínez-Lozano Aranaga
Fátima Martínez-Lozano Aranaga
MGMaria Jesús Gómez-Ramos
Maria Jesús Gómez-Ramos
MGMaría Bienvenida Gómez-Sánchez
María Bienvenida Gómez-Sánchez
FAFrancisco Valeriano Avilés
Francisco Valeriano Avilés
JRJuana Maria Morillas Ruiz
Juana Maria Morillas Ruiz
Malnutrition in critically ill patients represents a major concern as it can lead to adverse outcomes including increased morbidity and mortality. These patients exhibit an impaired immune response accompanied by increased oxidative stress. Nutritional support, including parenteral nutrition (PN), is critical in these patients. Intravenous lipid emulsions (ILEs), a key component of PN, provide energy and intervene in the modulation of inflammation. This was a secondary study of a randomized clinical trial at the Reina Sofia University Hospital (Murcia, Spain) for critically ill patients following major abdominal surgery that were administered PN supplemented with olive-oil-based ILE (OO-ILE, n = 29) or a mixed-lipid ILE (soybean oil, medium chain triglycerides, OO and fish oil, SMOF-ILE, n = 25). The effects on clinical outcomes, metabolic markers, oxidative stress, and inflammation were evaluated. No significant differences were observed between groups in the clinical parameters and outcomes, oxidative stress, or inflammatory markers. The within-group evaluation demonstrated an increase in total antioxidant capacity in both groups, while OO-ILE increased the levels of 15-F2t-isoprostane. In addition, the results showed that both mixtures reduced the release of IL-1β and IL-6. These findings suggest that both treatments had similar effects on oxidative stress and inflammatory response in this type of patient.

1 January 2020 in Nutrición Hospitalaria
Verified
Journal Article
Open access
FAFátima Martínez-Lozano Aranaga
Fátima Martínez-Lozano Aranaga
MRMaría Jesús Gómez Ramos
María Jesús Gómez Ramos
MÁMaria del Carmen Sánchez Álvarez
Maria del Carmen Sánchez Álvarez
Revista oficial de la Sociedad Española de Nutrición Parenteral y de la Sociedad Española de Nutrición. Está dedicada al estudio y divulgación de temas relacionados con la nutrición.

30 June 2016 in Nutrición Hospitalaria
Verified
Journal Article
Open access
PDF file
FAFátima Martínez-Lozano Aranaga
Fátima Martínez-Lozano Aranaga
Introducción: la composición lipídica de las fórmulas de nutrición parenteral (NP) se postula como posible factor de evolución clínica.Objetivo: evaluar las diferencias en efi cacia y seguridad de dos emulsiones lipídicas en NP.Material y métodos: estudio clínico prospectivo de pacientes posquirúrgicos sometidos a NP durante más de 7 días en un periodo de 2 años.Se administraron de forma indistinta 2 tipos de emulsiones lipídicas: enriquecida con ácidos grasos omega 3 (SMOFlipid Fresenius Kabi®) o conácido oleico omega 9 (Clinoleic Baxter®). Se analizaron variables epidemiológicas, analíticas, complicaciones infecciosas y mortalidad.Resultados: se estudió un total de 154 pacientes con edad media de 64,36 ± 13,73 años, de los que 95 eran hombres (61%), 78 (51%)recibieron SMOFlipid® y 76 (49%) Clinoleic®. La estancia media fue de 16,91 ± 4,23 días, la duración de la NP 9,68 ± 3,25 días y la mortalidaddel 11%. Se diagnosticaron 58 (37%) infecciones. No existieron diferencias signifi cativas en cuanto a los parámetros analíticos lipídicos,hepáticos o nutricionales (medidos al inicio y al 7.º día) ni en su evolución (estancia media, complicaciones infecciosas ni mortalidad) entre losdos grupos de pacientes.Conclusión: los pacientes sometidos a NP presentan similares características evolutivas con independencia de la emulsión lipídica utilizada.La bibliografía actual apunta a un benefi cio de la disminución del aporte de ácidos grasos omega 9, pero no se han encontrado diferenciassignifi cativas entre las fórmulas comparadas.

1 January 2014
Verified
Journal Article
Closed access
CÁCarmen Sánchez Álvarez
Carmen Sánchez Álvarez
MVMartín Vigil Velis
Martín Vigil Velis
EAErnest Barraza Aguirre
Ernest Barraza Aguirre
JSJulia María Hernández Serrano
Julia María Hernández Serrano
FAFátima Martínez-Lozano Aranaga
Fátima Martínez-Lozano Aranaga